What is BridgeBio Oncology Therapeutics, Inc.'s (BBOT) StockRank?

MoatMap's StockRank for BridgeBio Oncology Therapeutics, Inc. (BBOT) is 16/100, with a Strong Sell signal. This is a composite score combining Quality (33), Value (31), and Momentum (33) factor ranks across MoatMap's 20,000+ stock universe.

Does BridgeBio Oncology Therapeutics, Inc. have an economic moat?

BridgeBio Oncology Therapeutics, Inc. (BBOT) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is BridgeBio Oncology Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for BridgeBio Oncology Therapeutics, Inc. (BBOT) is Strong Sell, based on a StockRank of 16/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is BridgeBio Oncology Therapeutics, Inc. in?

BridgeBio Oncology Therapeutics, Inc. (BBOT) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

BBOT

STRONG SELL

BridgeBio Oncology Therapeutics, Inc. · Healthcare · United States · $707M · Avg Vol: $4M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-62.2%

D/E

0.0x

Dividend %

—

COMPANY DESCRIPTION

BridgeBio Oncology Therapeutics, Inc. is a biotechnology company dedicated to discovering and developing targeted therapies for genetically-driven cancers. Leveraging a precision medicine approach, the company focuses on specific mutations and molecular pathways to address unmet needs in oncology. It operates as a specialized subsidiary within the broader BridgeBio Pharma ecosystem, aiming to bring innovative cancer treatments from discovery to patients.

FINANCIAL SUMMARY (USD)

Year	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	0	0	0	—	—	—	—	—
EPS	-0.82	-0.94	-4.30	—	-1.89	-2.21	-2.11	—
Shares	79.2M	79.2M	80.0M	+1.0%	80.1M	—	—	—
Debt	—	0	2.8M	—	2.6M	—	—	—
Equity	-115.6M	-178.6M	411.1M	—	—	—	—	—
Op CF	-52.1M	-55.0M	-113.9M	—	-130.2M	—	—	—
Inv CF	-2.8M	-120.5M	73.3M	—	—	—	—	—
Fin CF	55.1M	206.3M	383.4M	—	—	—	—	—

Loading 1Y...

PRICE (1Y)+12.9%

SMA 50SMA 200

$8.75

RSI (14)

56.1

52W High

$14.87

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

-35.3%21.0

ROE

-62.2%15.3

GP/Assets

—N/A

Op. Margin

0.0%41.3

FCF/Assets

-19.2%19.6

Piotroski

321.7

Int. Cover

—N/A

D/E Ratio

0.01x86.6

Current Ratio

6.16x76.6

Value

P/E (TTM)

—N/A

EV/EBITDA

-2.5x25.0

P/FCF

—N/A

P/B

1.8x64.2

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

59%37.9

RS 6M

-38%23.1

SMA 50/200

0.81x20.5

EPS Rev 4W

+0.9%83.3

EPS Rev 12W

-2.9%31.0

EPS Improve

-11%17.0

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$707M

P/E (Forward)

-4.0x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BBOT are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
BBOT	BridgeBio Oncology Therapeutics, Inc.(you)	$707M	16	STRONG SELL
DRUG	Bright Minds Biosciences Inc.	$700M	17	STRONG SELL
CTMX	CytomX Therapeutics, Inc.	$705M	13	STRONG SELL
SGP	SpyGlass Pharma, Inc.	$685M	13	STRONG SELL
ACHV	Achieve Life Sciences, Inc.	$626M	17	STRONG SELL
ANNX	Annexon, Inc.	$855M	16	STRONG SELL
ALLO	Allogene Therapeutics, Inc.	$601M	18	STRONG SELL
ACRS	Aclaris Therapeutics, Inc.	$730M	21	SELL
0IL8.L	Kyntra Bio, Inc.	$666M	10	STRONG SELL
DNA	Ginkgo Bioworks Holdings, Inc.	$481M	15	STRONG SELL

Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%

BridgeBio Oncology Therapeutics, Inc. (BBOT) — Stock Score Summary

BridgeBio Oncology Therapeutics, Inc. (BBOT) has a MoatMap StockRank of 16/100 based on Quality (33/100), Value (31/100), and Momentum (33/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price	$8.75
Market Cap	$707M
P/E (Forward)	-4.00
Price/Book	1.81
Return on Equity	-62.2%
Return on Invested Capital	-35.3%
Debt/Equity	0.01x
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-86M

BridgeBio Oncology Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is BridgeBio Oncology Therapeutics, Inc.’s (BBOT) StockRank?: MoatMap’s StockRank for BridgeBio Oncology Therapeutics, Inc. (BBOT) is 16/100, with a Strong Sell signal. It is a composite of Quality (33), Value (31), and Momentum (33) factor ranks across MoatMap’s 20,000+ stock universe.
Does BridgeBio Oncology Therapeutics, Inc. have an economic moat?: BridgeBio Oncology Therapeutics, Inc. (BBOT) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is BridgeBio Oncology Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for BridgeBio Oncology Therapeutics, Inc. (BBOT) is Strong Sell, based on a StockRank of 16/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is BridgeBio Oncology Therapeutics, Inc. in?: BridgeBio Oncology Therapeutics, Inc. (BBOT) operates in the Healthcare sector, specifically the Biotechnology industry (United States).